

APPOINTMENT/RESIGNATION OF CFO AND COMPANY SECRETARY

-
- Mark Edwards appointed Chief Financial Officer (CFO) and Company Secretary, effective 2 November 2022
-
- Mr Edwards succeeds Tony Di Pietro, who has resigned, effective 11 November 2022
-

Melbourne, Australia, 6 October 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) advises that Tony Di Pietro has resigned as Chief Financial Officer and Company Secretary, effective 11 November 2022. Succeeding Mr Di Pietro will be Mark Edwards, who joins as Chief Financial Officer and Company Secretary, effective 2 November 2022.

Mark Edwards B.Acc., CA commences at INOVIQ on 2 November 2022. He is a highly experienced and capable CFO and Company Secretary with expertise in financial leadership and management, corporate governance, investor relations and corporate transactions. His most recent position was CFO and Company Secretary at Medical Developments International Ltd (ASX: MVP) for 8 years, where he managed over \$60 million in capital raisings, relocated the head office and manufacturing facility, established global infrastructure and operations and oversaw multiple new product launches. Previously he was Head of Finance and Company Secretary at Cogstate Ltd (ASX: CGS) and an Audit Senior Manager at Ernst & Young (EY) for 14 years, leading and managing professional staff in all aspects of audit, financial reporting, analysis and internal control across Manufacturing, Retail and Consumer Goods sectors, which included ASX listed clients.

Tony Di Pietro has been CFO and Company Secretary of INOVIQ and previously Sienna Cancer Diagnostics for the past eight years. He provided financial oversight for Sienna through its ASX-listing in 2017 through to its acquisition by BARD1 Life Sciences in 2020, and the post-acquisition integration over the past two years. Tony has agreed to assist with the handover to Mark Edwards as well as ensure that all preparations for the upcoming AGM are complete.

CEO Dr Leearne Hinch said: *"I have greatly enjoyed working with Tony for the past 2 years since the acquisition of Sienna Cancer Diagnostics. We wish Tony success in his future career."*

We're moving toward an important point in our commercialisation journey with several coming manufacturing, partnering and growth milestones. I welcome Mark's contribution to the next phase of INOVIQ's evolution as a next generation, precision diagnostics company."

Chairman Dr Geoff Cumming said: *"The Board is delighted to welcome Mark to the company and look forward to benefiting from the role that he will play in our continued evolution. On behalf of the Board, I would like to thank Tony for his financial leadership and the commitment he has provided through significant periods of growth and development within the company."*

Mark Edwards said: *"I look forward to contributing to the success of INOVIQ as it advances its plans to build a leading exosome and precision diagnostics business and prioritise commercial success both locally and abroad. With a number of key milestones targeted in the short to medium term, it's an exciting time to be joining a team and business committed to achieving its potential and delivering shareholder value."*

Authorised by the INOVIQ Board of Directors.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising next-generation exosome capture tools and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the EXO-NET pan-exosome capture tool for research purposes and the hTERT test as an adjunct to urine cytology testing for bladder cancer. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.